Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 13-22 years, at least two years post-menarche~* Body mass index (BMI, kg/m2) between 18 -30 kg/m2~* Surgical diagnosis of endometriosis~* Clinical decision to treat with a GnRH agonist, leuprolide depot (Lupron Depot®; TAP Pharmaceuticals, Inc.) 11.25 mg intra-muscular every 3 months~Exclusion Criteria:~* Concomitant chronic diseases which affect bone health, such as cystic fibrosis, inflammatory bowel disease, renal disease, or diabetes mellitus~* Markedly impaired liver function or liver failure~* Personal history of thromboembolic event (such as deep venous thrombosis)~* Medication use known to affect bone metabolism:~  * Glucocorticoid therapy (including inhaled steroids) or anticonvulsants used in the last 6 months

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 22 Years
- Healthy Volunteers: f

Study Arms:
- Norethindrone acetate + estrogens (Type: EXPERIMENTAL): Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + conjugated equine estrogens 0.625 mg by mouth daily for the 12 months of study participation.
- norethindrone acetate + placebo (Type: PLACEBO_COMPARATOR): Subjects randomized to the experimental arm received add-back therapy with norethindrone acetate 5 mg by mouth daily + a placebo capsule by mouth daily for the 12 months of study participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).